UPDATE: Synergy Pharma (SGYP) Reports In-Line Q3 EPS, Revenues Miss; Lowers FY18 Revenues Below Consensus & Below Min. Revenue Covenant on Loan Agreement

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 8/13/2026

1. CSCO
2. CBRS
3. COHR
4. WYFI
5. STUB
6. EAT
7. SPY
8. ANDG
9. GO
10. CRS

Go back to UPDATE: Synergy Pharma (SGYP) Reports In-Line Q3 EPS, Revenues Miss; Lowers FY18 Revenues Below Consensus & Below Min. Revenue Covenant on Loan Agreement

Synergy Pharmaceuticals Reports Third Quarter 2018 Financial Results and Business Update

November 8, 2018 5:00 PM EST

NEW YORK--(BUSINESS WIRE)-- Synergy Pharmaceuticals Inc. (NASDAQ: SGYP), a biopharmaceutical company focused on the development and commercialization of novel gastrointestinal (GI) therapies, today reported its financial results and business update for the three months ended September 30, 2018.

Third Quarter 2018 and Recent Highlights

TRULANCE® (plecanatide)

63,085 TRULANCE 30-count packs were dispensed in the third quarter of 2018, a 104.7% increase versus 30,825 in the prior year quarter, per IQVIA. 23,560 TRULANCE new prescriptions were filled in the third quarter of 2018, a 46.4% increase versus 16,089 in the prior year quarter, per IQVIA.... More